BIT.BIO
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the... cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
BIT.BIO
Industry:
Biotechnology Commercial Health Care
Founded:
2016-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.bit.bio
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
144.96 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager Amazon Google Maps Cloudflare COVID-19 Cloudflare Network Error Logging Cloudflare SSL
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
HealthVerity
HealthVerity powers the discovery, licensing, and linkage of traditional and emerging healthcare data.
Current Advisors List
Current Employees Featured
Founder
Investors List
Resilience
Resilience investment in Series B - bit.bio
Metaplanet Holdings
Metaplanet Holdings investment in Series B - bit.bio
ArchVentures SA
ArchVentures SA investment in Series B - bit.bio
Tencent
Tencent investment in Series B - bit.bio
Puhua Capital
Puhua Capital investment in Series B - bit.bio
Charles River Laboratories International
Charles River Laboratories International investment in Series B - bit.bio
Milad Alucozai
Milad Alucozai investment in Series B - bit.bio
Foresite Capital
Foresite Capital investment in Series B - bit.bio
Rick Klausner
Rick Klausner investment in Series A - bit.bio
BlueYard Capital
BlueYard Capital investment in Series A - bit.bio
Official Site Inspections
http://www.bit.bio Semrush global rank: 1.54 M Semrush visits lastest month: 16.98 K
- Host name: 199.60.103.36
- IP address: 199.60.103.36
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "bit.bio"
About us | bit.bio
What we do. bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting …See details»
Bit.bio - Wikipedia
Bit.bio was founded by Mark Kotter in 2016. bit.bio emerged as a spin out of the University of Cambridge to provide human cells for research, drug discovery and cell therapy. Initially named after Elpis the Greek Spirit of Hope, in 2019 the company rebranded as bit.bio, alluding to its application of genetic code (bit) to program biological cells (bio). In November 2021, Kathryn Penkus Corzo joined bit.bio as president and chief operating officer…See details»
bit.bio - Crunchbase Company Profile & Funding
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation …See details»
bit.bio Company Profile 2024: Valuation, Funding
When was bit.bio founded? bit.bio was founded in 2016. Where is bit.bio headquartered? bit.bio is headquartered in Cambridge, United Kingdom. What is the size of bit.bio? bit.bio has 200 total employees. What industry is bit.bio in? …See details»
Meet The Company Democratizing Access To Human …
Jun 1, 2023 Bit.bio was founded in 2016 by Mark Kotter and Florian Schuster to solve the biggest challenges facing stem cells by leveraging synthetic biology.See details»
Meet The Company Reprogramming The Future Of …
Apr 14, 2021 In June 2020, bit.bio announced it secured $41.5 million of funding from top investors, including Rick Klausner, Bob Nelsen, and Jim Tananbaum. Klausner discovered how T cells are activated, which ...See details»
Member profile: Bit Bio Ltd | BIA - BioIndustry
Founded in 2016 by Dr Mark Kotter, bit bio is an award-winning spinout from the University of Cambridge. By applying an engineering approach to synthetic and stem cell biology, Mark and …See details»
Venturing forth: bit.bio - reprogramming stem cells to …
Feb 16, 2022 Just five years on, bit.bio now has its headquarters in Cambridge’s Babraham Research Campus and another office in San Francisco, and employs more than 130 people. “Once we know the gene combinations that induce …See details»
bit.bio raises $103 million in first close of Series B …
Nov 5, 2021 bit.bio was founded in 2016 by Dr Mark Kotter from his labs at Cambridge University after his discovery of the opti-ox technology. Co-founder Florian Schuster joined in 2018 as the company continued to grow and …See details»
Powering the next generation of allogeneic therapies …
“At bit.bio, we are completely mission-focused on building upon the current successes of cell therapies,” said Paul Morrill, CBO of bit.bio. Morrill is a scientist who has worked in the ...See details»
bit.bio elevated to UK tech elite - Business Weekly
Mar 18, 2024 bit.bio is a synthetic biology company generating human cells for research, drug discovery and cell therapy. During 2023, bit.bio launched 17 new human iPSC-derived cell …See details»
bit.bio - Funding, Financials, Valuation & Investors - Crunchbase
Their latest funding was raised on May 1, 2024 from a Undisclosed round. bit.bio is funded by 17 investors. ZAKA VC and Resilience are the most recent investors. Unlock for freeSee details»
bit.bio - Cambridge&
Work started on what is now bit.bio’s opti-ox technology in 2012, in founder and CEO Mark Kotter’s research lab at Cambridge University. In 2017, his team showed that opti-ox works …See details»
Our platform for Reprogramming Cell Identity | Technology | bit.bio
At bit.bio we look at a cell as if it were a computer. The nucleus is the hard drive, storing genes in its DNA. Genes interact with one another, forming programs called gene regulatory networks. …See details»
bit.bio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. bit.bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 11. Number of Board …See details»
bit.bio Raises in Excess of $100 Million in First Close of Series B ...
Nov 5, 2021 Bit.bio was founded in 2016 by Dr Mark Kotter from his labs at Cambridge University after his discovery of the opti-ox technology. Co-founder Florian Schuster joined in …See details»
bit.bio is Industrialising Human Cell Manufacturing, Unleashing the ...
Jun 15, 2023 bit.bio’s ioCells are already being used and enable large-scale experiments that underpin preclinical research and drug development; The consistency of the cells is enabling …See details»
bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for ...
Nov 8, 2023 About bit.bio. bit.bio is a synthetic biology company focused on human cells that is advancing medicine (UN SDG9) and enabling curative treatments (UN SDG3). The company …See details»
Upcoming Events and Conferences | bit.bio
See the latest events and conferences that bit.bio is sponsoring, speaking or attending. Search. Cancel. Platform. Therapeutics. Therapeutics Cell therapies. Pipeline. Partnerships. ioCells. …See details»